FDA Approves Therapy for Cerebral Folate Deficiency - Summary - MDSpire

FDA Approves Therapy for Cerebral Folate Deficiency

Decision addresses a rare neurologic disorder linked to folate transport impairment.

  • By

  • Kathryn Wighton

  • March 10, 2026

  • 2 min

Share

Objective:

To announce the FDA's approval of Wellcovorin (leucovorin calcium) for treating cerebral folate deficiency associated with FOLR1 variants.

Approach:
    Key Findings:
    • Wellcovorin is the first FDA-approved treatment for cerebral folate deficiency associated with FOLR1 variants.
    • The therapy may benefit individuals with developmental delays and autistic features.
    • Adverse reactions to leucovorin include pruritus, rash, dyspnea, and anaphylaxis.
    Interpretation:

    The approval signifies a major advancement for patients with a previously untreated rare genetic condition, showcasing the potential of real-world evidence in regulatory decisions.

    Limitations:
    • The approval is specific to patients with confirmed FOLR1 variants.
    • Adverse reactions may limit the therapy's applicability in some patients.
    Conclusion:

    The FDA's approval of Wellcovorin represents a significant milestone in treating cerebral folate deficiency, providing hope for affected patients.

    Sources:

Original Source(s)

FDA Approves Therapy for Cerebral Folate Deficiency

  • by Kathryn Wighton

  • March 10, 2026

Related Content

Fabricated Citations Are Reaching Medical Journals

A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
Medical Oddities: Ancient Practice Calms Modern BP

Ancient workouts, anxious ears, tea gains, limb regrowth, and furry tongues collide.